BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

28 related articles for article (PubMed ID: 30351441)

  • 1. Correction: Impact of organised colorectal cancer screening on age-specific population incidences: evidence from a quasi-experimental study in Sweden.
    Strand GC; Strömberg U; Forsberg A; Bonander C
    Eur J Epidemiol; 2024 May; ():. PubMed ID: 38709418
    [No Abstract]   [Full Text] [Related]  

  • 2. Shifting the paradigm in high-risk prostate cancer: how good is TNM alone?
    Aoun F; Helou E; Albisinni S
    Prostate Cancer Prostatic Dis; 2023 Oct; ():. PubMed ID: 37884614
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
    Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
    Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies.
    Nordström T; Bratt O; Örtegren J; Aly M; Adolfsson J; Grönberg H
    Scand J Urol; 2016; 50(2):104-9. PubMed ID: 26625178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A paradigm shift for prostate cancer diagnostics].
    Bratt O
    Lakartidningen; 2018 Oct; 115():. PubMed ID: 30351441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prostate cancer - diagnostics and screening].
    Arnsrud Godtman R; Bratt O; Nordström T; Wallström J; Hugosson J
    Lakartidningen; 2024 Apr; 121():. PubMed ID: 38647107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
    Schröder FH; Roobol MJ
    Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of men with previous negative prostate biopsy.
    Perera M; Manning T; Finelli A; Lawrentschuk N
    Curr Opin Urol; 2016 Sep; 26(5):481-7. PubMed ID: 27314568
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.